SecBot SecBot
8-K ·Filed Apr 27, 2026

ORKA

Oruka Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed6mo ago SEC0001213900-26-047743
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

Monitor upcoming durability data in 2H 2026 and Phase 2b results in 2027, which will be critical for confirming the drug's long-term efficacy and dosing advantage. The strong safety profile reduces regulatory risk for future trials.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$76.39
T+0 close · Apr 27, 2026 · via day close
Latest settled
+21.13%
T+60 · $92.53
Vs SPY
+16.35%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $76.39entry
  2. T+1 · 7mo ago −3.14%α −2.66% · $73.99
  3. T+5 · 7mo ago −13.00%α −13.40% · $66.46
  4. T+20 · 6mo ago −22.69%α −27.64% · $59.06
  5. T+60 · 4mo ago +21.13%α +16.35% · $92.53
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oruka Therapeutics announced positive Phase 2a trial results for its anti-IL-23 antibody ORKA-001 in psoriasis, showing 63.5% of patients achieved complete skin clearance (PASI 100) at 16 weeks with a favorable safety profile. The data supports potential annual dosing and positions ORKA-001 as a best-in-class therapy in a $30B+ market.

Key Facts

  • 63.5% of ORKA-001-treated patients achieved PASI 100 (complete skin clearance) at Week 16 vs. 4.8% for placebo (p < 0.0001)
  • Favorable safety profile: no serious adverse events in treatment arm, TEAE rate (50.8%) lower than placebo (57.1%)
  • Updated PK data supports potential for annual dosing, with drug concentrations remaining above effective levels for a full year
  • Phase 2b trial (EVERLAST-B) ongoing with data expected in 2027 to support Phase 3 initiation
  • Company is well-funded with cash runway into Phase 3 for ORKA-001

Financial Impact

Significant positive impact on valuation potential in a $30B+ psoriasis market

market caprevenue potentialcash runway

Risk Factors

  • Phase 2a results may not be replicated in larger Phase 3 trials
  • Competitors in the IL-23 inhibitor space could respond with improved data or pricing
  • Longer-term safety data could reveal issues not seen in the 16-week trial

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-047743
Document: ea028778201ex99-2.htm0001213900-26-047743
Document: ea028778201ex99-1.htm0001213900-26-047743
Document: 0001213900-26-047743-index-headers.html0001213900-26-047743
Document: 0001213900-26-047743-index.html0001213900-26-047743
Document: 0001213900-26-047743.txt0001213900-26-047743

Track record

40 reports on ORKA

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 10 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
  3. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
  4. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  6. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  7. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
  8. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  9. Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
Showing 10 of 40

US Market Status

Market Closed · Opens in 8h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026